OGN - Organon - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68622V1061

Contraceptives, Fertility medicines, Biosimilars, Oncology products, Cholesterol medicines

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey. Web URL: https://www.organon.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for OGN - Organon  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for OGN - Organon  - Stock Price & Dividends

OGN Stock Overview

Market Cap in USD 5,395m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2021-06-02

OGN Stock Ratings

Growth 5y -25.0
Fundamental -4.71
Dividend 56.3
Rel. Performance vs Sector 2.28
Analysts 3.44/5
Fair Price Momentum 25.48 USD
Fair Price DCF 52.08 USD

OGN Dividends

Dividend Yield 12m 5.05%
Yield on Cost 5y 3.89%
Dividends CAGR 5y 25.99%
Payout Consistency 99.3%

OGN Growth Ratios

Growth 12m 6.88%
Growth Correlation 12m 30%
Growth Correlation 3m 17%
CAGR 5y -7.81%
CAGR/Mean DD 5y -0.25
Sharpe Ratio 12m 0.04
Alpha vs SP500 12m -10.72
Beta vs SP500 5y weekly 0.79
ValueRay RSI 83.59
Volatility GJR Garch 1y 29.90%
Price / SMA 50 6.02%
Price / SMA 200 30.84%
Current Volume 987.6k
Average Volume 20d 1444.5k

External Links for OGN Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of OGN stocks?
As of July 27, 2024, the stock is trading at USD 22.19 with a total of 987,601 shares traded.
Over the past week, the price has changed by +5.77%, over one month by +7.56%, over three months by +21.28% and over the past year by +7.85%.
What are the forecast for OGN stock price target?
According to ValueRays Forecast Model, OGN Organon will be worth about 27.5 in July 2025. The stock is currently trading at 22.19. This means that the stock has a potential upside of +24.02%.
Issuer Forecast Upside
Wallstreet Target Price 22.5 1.40
Analysts Target Price 29.3 32.0
ValueRay Target Price 27.5 24.0